分红方面，圣诺生物A股上市后累计派现8713.72万元。近三年，累计派现6313.72万元。 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 责任编辑：小浪快报 融资方面，圣诺生物当日融资买入1305.15万元。当前融资余额4.64亿元，占流通市值的7.53%，融资余 额低于近一年50%分位水平，处于较低位。 融券方面，圣诺生物1月29日融券偿还0.00股，融券卖出2700.00股，按当日收盘价计算，卖出金额10.56 万元；融券余量3900.00股，融券余额15.26万元，超过近一年90%分位水平，处于高位。 资料显示，成都圣诺生物科技股份有限公司位于四川省成都市大邑县大安路98号，成立日期2001年7月 23日，上市日期2021年6月3日，公司主营业务涉及多肽创新药CDMO服务,自主研发、销售的多肽原料 药和制剂产品,多肽类产品定制生产服务,以及多肽药物生产技术转让服务。主营业务收入构成为：原料 药55.95%，制剂25.10%， ...

Group 1 - The core advantage of generic drugs is the lower R&D investment required [1] - GLP-1 peptide drugs are well-known for their triple benefits: blood sugar reduction, weight loss, and cardiovascular protection, making them a highly competitive area in innovative pharmaceuticals [3] - Saintno Biological (688117.SH), a company listed on the Sci-Tech Innovation Board, focuses on providing CDMO services for innovative peptide drugs and developing raw materials and formulations for generic peptides [4][5] Group 2 - According to the third-quarter earnings forecast disclosed by Saintno Biological in mid-October, the expected net profit for the first three quarters is between 114 million to 140 million, representing a year-on-year growth of 100.53% to 145.10% [6] - The expected non-net profit for the same period is between 113 million to 138 million, with a year-on-year growth of 111.26% to 158.21% [6]

Core Viewpoint - Shengnuo Bio experienced a decline of 3.35% in stock price on August 26, with a trading volume of 271 million yuan, indicating market volatility and investor sentiment [1] Financing Summary - On August 26, Shengnuo Bio had a financing buy-in amount of 39.54 million yuan and a financing repayment of 35.05 million yuan, resulting in a net financing buy of 4.49 million yuan [1] - The total financing and securities balance for Shengnuo Bio reached 516 million yuan, accounting for 7.73% of its circulating market value, which is above the 90th percentile of the past year [1] - The company had no short selling activity on August 26, with a short selling balance of 0.00 yuan, indicating a lack of bearish sentiment [1] Business Overview - Shengnuo Bio, established on July 23, 2001, and listed on June 3, 2021, is located in Chengdu, Sichuan Province [1] - The company's main business includes peptide innovative drug CDMO services, self-developed and sold peptide raw materials and formulations, custom production services for peptide products, and technology transfer services for peptide drug production [1] - The revenue composition of Shengnuo Bio is as follows: raw materials 55.95%, formulations 25.10%, pharmaceutical research 12.43%, custom production 5.31%, other 1.20%, and contract processing 0.01% [1] Financial Performance - As of June 30, the number of shareholders for Shengnuo Bio reached 11,100, an increase of 50.98% compared to the previous period, while the average circulating shares per person decreased by 7.27% to 14,136 shares [2] - For the first half of 2025, Shengnuo Bio reported a revenue of 338 million yuan, representing a year-on-year growth of 69.69%, and a net profit attributable to shareholders of 88.96 million yuan, reflecting a significant increase of 308.29% [2] Dividend Information - Since its A-share listing, Shengnuo Bio has distributed a total of 82.14 million yuan in dividends, with 58.14 million yuan distributed over the past three years [3] Institutional Holdings - As of June 30, 2025, several institutions exited the top ten circulating shareholders of Shengnuo Bio, including Yuanxin Yongfeng Ju You A, China Merchants Pharmaceutical Health Industry Stock, and Huaan Manufacturing Upgrade One-Year Holding Mixed A [3]

Core Viewpoint - Shengnuo Biotech (688117.SH) has reported significant growth in its half-year performance for 2025, with net profit expected to increase by 253.54% to 332.1% year-on-year, driven by strong performance in its peptide raw material business [1][3]. Financial Performance - The company anticipates a net profit of between 77.03 million yuan and 94.14 million yuan for the first half of 2025, with a year-on-year increase of 253.54% to 332.1% [1][3]. - The expected non-deductible net profit is projected to be between 77.35 million yuan and 94.53 million yuan, reflecting a year-on-year increase of 304.49% to 394.38% [1][3]. - In 2024, Shengnuo Biotech reported revenue of 456 million yuan, a year-on-year growth of 4.84%, while net profit decreased by 28.88% to 50.02 million yuan due to increased R&D investment and other factors [2]. Business Operations - Shengnuo Biotech is actively expanding its production capacity to meet market demand, with projects such as the "Annual Production of 395 kg Peptide Raw Material Production Line" and the expansion of raw material workshops [3]. - The company has successfully launched its 106 workshop and is in the equipment validation phase for workshops 107 and 108 [3]. Market Expansion - The global peptide CDMO market is projected to reach $11.8 billion by 2030, with the domestic market expected to reach 18.5 billion yuan, indicating a higher CAGR than the global market [4]. - Shengnuo Biotech's overseas revenue reached 148 million yuan in 2024, a significant increase of 73.93%, while domestic revenue decreased by 12.51% to 303 million yuan [4]. - The proportion of overseas revenue has increased to 32.52%, up 12.92 percentage points from 2023, reflecting the company's focus on expanding its international sales channels [4]. R&D and Product Development - The company is collaborating with external firms to develop various peptide products and has significantly increased its R&D investment, with expenses rising from 13.75 million yuan in 2021 to 49.17 million yuan in 2024 [5]. - Shengnuo Biotech provides CDMO services for over 40 peptide innovation drug projects, with two products approved for commercialization and two in the production application stage [5].